Actively Recruiting
Phase 1 Study Comparing Pharmacokinetics of Y-4 Tablets, Pregabalin Capsules, and Riluzole Tablets in Healthy Adults Under Fasting Conditions
Led by Beijing Tiantan Hospital · Updated on 2025-04-20
10
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new drug called Y-4, which combines pregabalin and riluzole, in healthy adult volunteers aged 18 to 45 years. The goal is to compare how Y-4 is processed in the body pharmacokinetics with the individual drugs pregabalin and riluzole taken separately. This phase 1, open-label study focuses on understanding the drugs behavior when taken after fasting. Participants will take part in three separate treatment periods with a 7-day break in between. In each period, subjects will receive a single oral dose one Y-4 tablet containing 112.5 mg pregabalin and 28.125 mg riluzole, one pregabalin capsule 75 mg, or one riluzole tablet 50 mg. Each dose is given in a fasting state, and participants will stay at the research center for monitoring during and after dosing. During each period, blood samples will be collected for up to 72 hours to measure drug levels and monitor safety. Researchers will track adverse events, lab tests, heart activity, vital signs, physical exams, oxygen levels, and specific scales for safety up to about 25 days after dosing. Participants will be monitored closely throughout the study for any abnormal results and overall health, with the study lasting through all three dosing periods and follow-ups.
CONDITIONS
Brief Title
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
Research Team
Y
Ya Shu Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here